Oleclumab (INN;[1] development code MEDI9447) is a human monoclonal antibody targeting the ectonucleotidase CD73 that was designed for the treatment of pancreatic and colorectal and other cancers.[2]

This drug was developed by MedImmune/AstraZeneca.[3]

References

  1. ^ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
  2. ^ ClinicalTrial.gov for Oleclumab
  3. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Oleclumab, American Medical Association.
Allikas: https://en.wikipedia.org/wiki/Oleclumab
No tags for this post.